FDA Panel Says Bivalent Shots, Not Original COVID-19 Vaccines, Should Be Standard
The FDA’s vaccine advisory panel has recommended that the FDA phase out the original versions of the COVID-19 vaccines in favor of the updated bivalent booster shots.
The FDA’s vaccine advisory panel has recommended that the FDA phase out the original versions of the COVID-19 vaccines in favor of the updated bivalent booster shots.
The bivalent COVID-19 vaccines seem to provide protection against symptomatic infection with BA.5 and XBB/XBB.1.5 SARS-CoV-2 variants.
Most immunocompromised adults studied did not adhere to CDC recommendations regarding booster doses of the monovalent COVID-19 vaccines.
The FDA has asked its vaccine advisory committee to consider a proposal to turn COVID-19 vaccines into an annual shot for most Americans.
Patients with cancer have a higher risk of breakthrough SARS-CoV-2 infection and worse COVID-19 outcomes than patients without cancer.
The inhaled vaccine was approved in September by Chinese regulators after completing trials in China, Hungary, Pakistan, Malaysia, Argentina, and Mexico.
People with Medicare or Medicaid and those with private health insurance would likely get the vaccine for free, according to a Pfizer executive.
COVID-19 vaccination is safe for cancer patients receiving immune checkpoint inhibitors and should not interrupt therapy, according to researchers.
The booster dose elicited robust antibody responses comparable to or exceeding levels associated with the efficacy data in the primary series of the vaccine.
The Moderna bivalent vaccine is authorized for children age 6 and older, and the Pfizer-BioNTech vaccine is authorized for children age 5 and older.